J-C Becker

2.8k total citations · 1 hit paper
17 papers, 2.1k citations indexed

About

J-C Becker is a scholar working on Rheumatology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, J-C Becker has authored 17 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 7 papers in Pathology and Forensic Medicine and 6 papers in Genetics. Recurrent topics in J-C Becker's work include Rheumatoid Arthritis Research and Therapies (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). J-C Becker is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). J-C Becker collaborates with scholars based in United States, France and Germany. J-C Becker's co-authors include Maxime Dougados, Michael Schiff, J. Teng, Daniel Aletaha, George A. Wells, Josef S Smolen, Piet L. C. M. van Riel, R. Aranda, René Westhovens and Charles Peterfy and has published in prestigious journals such as Annals of the Rheumatic Diseases, World Journal of Gastroenterology and International Journal of Oncology.

In The Last Decade

J-C Becker

16 papers receiving 2.0k citations

Hit Papers

Validation of the 28-joint Disease Activity Score (DAS28)... 2008 2026 2014 2020 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
    2008 624 citations George A. Wells, J-C Becker et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J-C Becker United States 13 1.7k 745 484 431 365 17 2.1k
J.H.L.M. van Groenendael Netherlands 16 1.9k 1.1× 744 1.0× 324 0.7× 406 0.9× 282 0.8× 22 2.1k
Y P M Goekoop-Ruiterman Netherlands 20 2.4k 1.4× 880 1.2× 399 0.8× 485 1.1× 348 1.0× 30 2.6k
A. Gerards Netherlands 14 1.7k 1.0× 749 1.0× 336 0.7× 383 0.9× 268 0.7× 29 2.0k
William Palmer United States 17 1.6k 1.0× 757 1.0× 360 0.7× 448 1.0× 219 0.6× 24 2.1k
J. Christiaan van Denderen Netherlands 16 1.8k 1.1× 631 0.8× 441 0.9× 248 0.6× 223 0.6× 26 2.2k
K. H. Han Netherlands 10 1.6k 0.9× 633 0.8× 243 0.5× 355 0.8× 252 0.7× 16 1.8k
M. Lange United States 6 1.7k 1.0× 941 1.3× 574 1.2× 277 0.6× 234 0.6× 7 2.2k
Sofia Ernestam Sweden 22 1.2k 0.7× 452 0.6× 326 0.7× 319 0.7× 219 0.6× 44 1.6k
John Han United States 17 1.9k 1.1× 831 1.1× 754 1.6× 261 0.6× 154 0.4× 20 2.3k
André J. Peeters Netherlands 12 1.8k 1.1× 707 0.9× 200 0.4× 312 0.7× 267 0.7× 15 2.0k

Countries citing papers authored by J-C Becker

Since Specialization
Citations

This map shows the geographic impact of J-C Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-C Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-C Becker more than expected).

Fields of papers citing papers by J-C Becker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J-C Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-C Becker. The network helps show where J-C Becker may publish in the future.

Co-authorship network of co-authors of J-C Becker

This figure shows the co-authorship network connecting the top 25 collaborators of J-C Becker. A scholar is included among the top collaborators of J-C Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-C Becker. J-C Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Anders, Sven, et al.. (2017). Facilitators of high-quality teaching in medical school: findings from a nation-wide survey among clinical teachers. BMC Medical Education. 17(1). 178–178. 18 indexed citations
2.
Bathon, Joan M., M. Robles, Antônio Carlos Ximenes, et al.. (2011). Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Annals of the Rheumatic Diseases. 70(11). 1949–1956. 67 indexed citations
3.
Schiff, Michael, M. Keiserman, C. Codding, et al.. (2011). Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Annals of the Rheumatic Diseases. 70(11). 2003–2007. 46 indexed citations
4.
Emery, P., Patrick Durez, M Dougados, et al.. (2009). Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Annals of the Rheumatic Diseases. 69(3). 510–516. 190 indexed citations
5.
Westhovens, René, M. Robles, Antônio Carlos Ximenes, et al.. (2009). Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases. 68(12). 1870–1877. 262 indexed citations
6.
Russell, A. S., P. Emery, Carlos Abud‐Mendoza, et al.. (2009). P32 Abatacept demonstrates consistent safety and sustained improvements in efficacy through 5 years of treatment in biologic-naïve patients with RA. Indian Journal of Rheumatology. 4(3). S13–S14. 12 indexed citations
7.
Peterfy, Charles, René Westhovens, J-C Becker, et al.. (2009). P31 Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA. Indian Journal of Rheumatology. 4(3). S13–S13. 10 indexed citations
8.
Merrill, JT, Rubén Burgos‐Vargas, René Westhovens, et al.. (2008). The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study. Queensland's institutional digital repository (The University of Queensland). 58(12). 4031–4032. 15 indexed citations
9.
Wells, George A., J-C Becker, J. Teng, et al.. (2008). Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Annals of the Rheumatic Diseases. 68(6). 954–960. 624 indexed citations breakdown →
10.
Genant, H K, Charles Peterfy, René Westhovens, et al.. (2007). Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Annals of the Rheumatic Diseases. 67(8). 1084–1089. 112 indexed citations
11.
Genovese, Mark C., M. Schiff, Michael E. Luggen, et al.. (2007). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Annals of the Rheumatic Diseases. 67(4). 547–554. 204 indexed citations
12.
13.
Russell, Anthony S., Gene V. Wallenstein, Michael C. Martin, et al.. (2006). Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases. 66(2). 189–194. 57 indexed citations
14.
Becker, J-C, Carsten Müller‐Tidow, M Stolte, et al.. (2006). Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. International Journal of Oncology. 29(3). 615–23. 12 indexed citations
15.
Becker, J-C. (2006). Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. World Journal of Gastroenterology. 12(21). 3297–3297. 40 indexed citations
16.
Moreland, Larry W., et al.. (2006). AN INTEGRATED SAFETY ANALYSIS OF ABATACEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) ACROSS PATIENT TYPES AND BACKGROUND THERAPIES. JCR Journal of Clinical Rheumatology. 12(Supplement). S46–S47. 3 indexed citations
17.
Westhovens, René, Piet L. C. M. van Riel, Jean Sibilia, et al.. (2004). Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment. Arthritis Research. 6(Suppl 1). 86–86.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.H.L.M. van Groenendael Breakdown of academic impact, for papers by Y P M Goekoop-Ruiterman Breakdown of academic impact, for papers by A. Gerards Breakdown of academic impact, for papers by William Palmer Breakdown of academic impact, for papers by J. Christiaan van Denderen Breakdown of academic impact, for papers by K. H. Han Breakdown of academic impact, for papers by M. Lange Breakdown of academic impact, for papers by Sofia Ernestam Breakdown of academic impact, for papers by John Han Breakdown of academic impact, for papers by André J. Peeters
Rankless by CCL
2026